ITALY, Torino, July 22nd, 2022. ELITechGroup S.p.A. is pleased to announce a strategic partnership with Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus) for monkeypox virus testing across Europe. The Monkeypox Virus Real Time PCR Kit from Bioperfectus in combination with the fully automated sample-to-result ELITe InGenius and BeGenius instruments from ELITechGroup will address the needs of major reference laboratories, hospitals, and disease control centers in Europe.
Bioperfectus launched the Monkeypox Virus Real Time PCR Kit with CE marking on May 24th, 2022. Based on real-time PCR technology, the kit is specifically designed on the F3L gene areas of the monkeypox virus. In addition, the kit also contains a housekeeping gene (RNase P) as an internal control (IC) for specimen sampling and nucleic acid extraction.
BioPerfectus and ELITechGroup are collaborating to provide the BioPerfectus Monkeypox Virus Real Time PCR Kit exclusively for ELITe InGenius and BeGenius instruments to offer the first fully automated monkeypox diagnostic solution on the market. Both parties aim to support diagnostic capacity to fight the monkeypox outbreak.
According to the World Health Organization, real-time PCR is the preferred method for monkeypox virus surveillance given its accuracy and sensitivity. ELITechGroup is thrilled to gain Bioperfectus as a solid partner in monkeypox virus testing in Europe.
About ELITechGroup:
ELITechGroup S.p.A. is the headquarter of the Molecular Diagnostics division of ELITechGroup, which develops innovative molecular diagnostic solutions targeted for infectious diseases. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup manufactures and distributes diagnostic products for clinical chemistry, microbiology, hematology, and molecular biology through direct sales and a distribution network encompassing more than 100 countries. For more information, please visit www.elitechgroup.com.
About Bioperfectus:
Bioperfectus, a publicly listed company on the Shanghai Stock Exchange (SSE:688399), has been a leading molecular diagnostic solution provider specializing in infectious diseases since 2010. With headquarters in Jiangsu, and subsidiaries in Shanghai, Beijing, Xi’an, Taizhou, Hainan, and Yinchuan, Bioperfectus is a pioneer in the molecular diagnostics market with products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automated laboratory devices. Young and passionate, Bioperfectus is working steadily and firmly to achieve the dream of creating a healthier future for our next generations. For more information, please visit www.bioperfectus.com.
“
